Jan 22 (Reuters) - Aurinia Pharmaceuticals Inc AUP.TO :
* AURINIA ANNOUNCES VOCLOSPORIN OPHTHALMIC SOLUTION DEMONSTRATES STATISTICALLY SUPERIOR EFFICACY VERSUS RESTASIS® IN A PHASE 2 HEAD-TO-HEAD STUDY FOR THE TREATMENT OF DRY EYE SYNDROME
* AURINIA PHARMACEUTICALS INC - PRIMARY ENDPOINT OF DROP DISCOMFORT AT 1-MINUTE ON DAY 1 SHOWED NO STATISTICAL DIFFERENCE BETWEEN VOS AND RESTASIS
* AURINIA PHARMACEUTICALS INC - NO SERIOUS ADVERSE EVENTS WERE REPORTED IN STUDY, AND THERE WERE NO UNEXPECTED SAFETY SIGNALS.